Breaking News Instant updates and real-time market news.

2023-03-29 11:01:59 NAAS NaaS $7.35 / +0.69 (+10.36%) 11:01 03/29/23 03/29 11:01 03/29/23 11:01	NaaS, Smart Order establish 'Smart Charging' joint venture NaaS Technology and Smart Order announced the establishment of a joint venture, "Smart Charging", to create a network of destination-sharing charging services for electric vehicles. Under this new collaboration, NaaS and Smart Order will leverage their respective advantages in charging station infrastructure, operational expertise, product technology, lodging networks, services, and more to upgrade the integrated charging services for commercial lodges.

2023-03-29 11:01:59

NAAS

NaaS

$7.35 / +0.69 (+10.36%)

11:01

03/29/23

03/29

11:01

03/29/23

11:01

NaaS, Smart Order establish 'Smart Charging' joint venture

NaaS Technology and Smart Order announced the establishment of a joint venture, "Smart Charging", to create a network of destination-sharing charging services for electric vehicles. Under this new collaboration, NaaS and Smart Order will leverage their respective advantages in charging station infrastructure, operational expertise, product technology, lodging networks, services, and more to upgrade the integrated charging services for commercial lodges.

OTHER BREAKING NEWS FROM THE FLY

Initiation	Crispr Therapeutics resumed with an Outperform at William Blair » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) William Blair resumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 04/27/23 Crispr Therapeutics CEO Kulkarni sells $1.3M in company shares 04/03/23 Vertex Pharmaceuticals, Crispr Therapeutics complete rolling BLAs to FDA 03/29/23 Crispr Therapeutics announces departure of board member 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/23/23 Citi Crispr Therapeutics price target raised to $70 from $55 at Citi 05/09/23 Stifel Crispr Therapeutics price target lowered to $64 from $69 at Stifel 04/13/23 Cantor Fitzgerald Cantor starts Crispr Therapeutics at Overweight on commercialization chances 04/13/23 Cantor Fitzgerald Crispr Therapeutics initiated with an Overweight at Cantor Fitzgerald CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/08/23 Crispr Therapeutics reports Q1 EPS (67c), consensus ($1.70) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 04/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/23 Fly Intel: Pre-market Movers 06/02/23 2023 ASCO Annual Meeting CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/26/23 Crispr Therapeutics put volume heavy and directionally bearish 05/11/23 Crispr Therapeutics put volume heavy and directionally bearish 05/09/23 Crispr Therapeutics call volume above normal and directionally bullish 05/08/23 Crispr Therapeutics options imply 4.2% move in share price post-earnings
Hot Stocks	Aurora Europe, Ethypharm chosen to supply dried medical cannabis flower » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 ACB Aurora Cannabis / + Aurora Europe GmbH, a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ACB Aurora Cannabis / + 04/27/23 Bipartisan lawmakers reintroduce Safe Banking Act for cannabis businesses 04/26/23 Aurora Cannabis partners with Strainprint for tracking program 04/17/23 Curaleaf spikes over 7% after NJ CRC Board reverses, okays adult use renewals 03/24/23 Aurora Cannabis announces Nasdaq notice of non-compliance ACB Aurora Cannabis / + 02/13/23 CIBC Aurora Cannabis price target lowered to C$1.75 from C$2.25 at CIBC 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2 at Canaccord 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2.00 at Canaccord 01/27/23 Stifel Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel ACB Aurora Cannabis / + 02/09/23 Aurora Cannabis reports Q2 adjusted EBITDA C$1.4M vs. (C$7.1M) a year ago 02/09/23 Aurora Cannabis reports Q2 revenue C$61.7M vs. C$60.6M a year ago ACB Aurora Cannabis / + 04/21/23 Booker says lawmakers to revive cannabis banking bill, Marijuana Moment says 12/27/22 FDA explores regulating CBD in foods, supplements, WSJ reports 12/05/22 Defense bill with marijuana reform attached is delayed, Marijuana Moment says ACB Aurora Cannabis / + 05/11/23 Here's What You Missed in Cannabis, Psychedelics This Week 05/04/23 Here's What You Missed in Cannabis This Week 04/20/23 Here's What You Missed in Cannabis This Week 04/13/23 Here's What You Missed in Cannabis This Week ACB Aurora Cannabis / + 05/24/23 Largest borrow rate increases among liquid names 05/23/23 Largest borrow rate increases among liquid names 05/22/23 Aurora Cannabis options imply 17.4% move in share price post-earnings 05/18/23 Aurora Cannabis options imply 11.0% move in share price post-earnings
Syndicate	Oculis offers to sell 5M shares of common stock » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 OCS Oculis $11.62 / -0.48 (-3.97%) BofA Securities and SVB… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events OCS Oculis $11.62 / -0.48 (-3.97%) 05/22/23 Oculis' OCS-01 eye drops meet efficacy endpoint in Phase 3 macular edema trial 04/26/23 Oculis opens new office in Boston, appoints Fang Li as SVP, regulatory affairs 04/04/23 Oculis to host call to discuss late-stage pipeline, near-term milestones 03/16/23 Oculis completes enrollment in Phase 3 OCS-01 OPTIMIZE trial OCS Oculis $11.62 / -0.48 (-3.97%) 05/10/23 Pareto Oculis initiated with a Buy at Pareto 04/28/23 Wedbush Oculis initiated with an Outperform at Wedbush OCS Oculis $11.62 / -0.48 (-3.97%) 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/23 Biotech/Biopharma
Hot Stocks	Atea Pharmaceuticals board rejects unsolicited proposal from Tang Capital » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) Atea Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Earnings Events AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) 05/23/23 Atea Pharmaceuticals confirms receipt of Concentra Biosciences proposal 05/22/23 Atea Pharmaceuticals up 37% after buyout offer from Tang Capital 05/22/23 Tang Capital reports 3.6% stake in Atea Pharmaceuticals 04/25/23 Atea Pharmaceuticals announces U.S. FDA FTD granted to bemnifosbuvir AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) 05/08/23 Atea Pharmaceuticals reports Q1 EPS (43c), consensus (48c) 02/28/23 Atea Pharmaceuticals reports Q4 EPS (41c), consensus (45c) 06/16/23 Atea Pharmaceuticals, Inc.
Hot Stocks	Arcimoto announces availability of new Arcimoto MUV » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 FUV Arcimoto $1.54 / +0.09 (+6.21%) Arcimoto announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events FUV Arcimoto $1.54 / +0.09 (+6.21%) 05/09/23 Arcimoto announces strategic agreement with Faction Technology 04/20/23 Arcimoto appoints Chris Dawson as CEO 03/01/23 Arcimoto opens vehicles sales in 4 new states 02/21/23 Arcimoto to begin 2023 vehicle production for spring deliveries FUV Arcimoto $1.54 / +0.09 (+6.21%) 02/15/23 Dawson James Arcimoto upgraded to Neutral from Sell at Dawson James 12/01/22 Alliance Global Partners Arcimoto price target raised to $11 from $7 at Alliance Global Partners 09/06/22 Dawson James Arcimoto downgraded to Sell from Neutral at Dawson James 06/21/22 Dawson James Arcimoto producing more cars but still needs cash, says Dawson James 18 Jan FUV Arcimoto $1.54 / +0.09 (+6.21%) 01/17/23 Fly Intel: After-Hours Movers 06/16/23 Arcimoto, Inc.
Upgrade	Knot Offshore Partners upgraded to Buy from Neutral at Alliance Global Partners » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) Alliance Global Partners… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 04/10/23 Knot Offshore Partners CEO, CFO Gary Chapman steps down 01/12/23 Knot Offshore Partners falls -37.9% 01/12/23 Knot Offshore Partners falls -43.3% 01/12/23 Knot Offshore Partners falls -40.5% KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 02/01/23 Alliance Global Partners Knot Offshore Partners upgraded to Neutral from Sell at Alliance Global Partners 01/12/23 Alliance Global Partners Knot Offshore Partners downgraded to Sell from Buy at Alliance Global Partners 01/06/23 B. Riley Knot Offshore Partners price target lowered to $15 from $22 at B. Riley 12/13/22 Alliance Global Partners Knot Offshore Partners initiated with a Buy at Alliance Global Partners KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 05/25/23 Knot Offshore Partners reports Q1 operating income $17.7M vs. $19.6M in Q4 KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 01/12/23 What You Missed On Wall Street On Thursday 01/12/23 What You Missed On Wall Street This Morning
Hot Stocks	Diebold signs debt restructuring agreement with key stakeholders » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 DBD Diebold / + Diebold has entered into… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options DBD Diebold / + 05/05/23 Diebold receives continued listing standard notice from NYSE 03/21/23 Diebold confirms closing on $55M of additional liquidity 03/16/23 Diebold down 9%, sees risk to generating cash to sustain operating needs 02/06/23 Diebold announces Octavio Marquez was elected Chairman DBD Diebold / + 05/04/23 Wedbush Wedbush downgrades Diebold to Neutral, lowers price target to $1 05/04/23 Wedbush Diebold downgraded to Neutral from Outperform at Wedbush 03/17/23 Wedbush Wedbush keeps Outperform rating on Diebold after mid-quarter update 10/24/22 DA Davidson Diebold downgraded to Neutral from Buy at DA Davidson DBD Diebold / + 05/03/23 Diebold sees FY23 revenue $3.7B-$3.9B, consensus $3.82B 05/03/23 Diebold reports Q1 non-GAAP EPS (85c), consensus 7c 02/09/23 Diebold reports Q4 adjusted EPS 79c, consensus 38c DBD Diebold / + 04/11/23 Largest borrow rate increases among liquid names 04/10/23 Largest borrow rate increases among liquid names
Hot Stocks	Telesat Holdings selects SFL to manufacture LEO 3 demonstration satellite » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) Telesat announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Earnings TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) 02/08/23 Mynaric delivers CONDOR Mk2terminals to Telesat Government Solutions 02/07/23 Telesat selected by Anuvu to provide antennas, ground-station infrastructure 12/19/22 Telesat Holdings appoints Harlow as President of Telesat Government Solutions 12/15/22 Spacecom completes testing campaign of Telesat's LEO demonstration satellite TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) 05/11/23 Telesat Holdings sees 2023 revenue C$690M-C$710M 05/11/23 Telesat Holdings reports Q1 EPS C$0.60 vs. C$1.13 last year 03/29/23 Telesat Holdings sees FY23 revenue $690M-$710M 03/29/23 Telesat Holdings reports Q4 EPS C$1.76 vs C$1.28 last year
Hot Stocks	Veeva, Lotus Clinical Research expand partnership » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 VEEV Veeva $165.49 / +2.58 (+1.58%) Veeva Systems announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options VEEV Veeva $165.49 / +2.58 (+1.58%) 05/24/23 Veeva products selected by Minaris Regenerative Medicine 05/23/23 Veeva, UCB collaborate in patient experience and trial solutions 05/10/23 Sanofi is implementing Veeva tools to modernize its quality system 04/11/23 Cognizant and Boehringer Ingelheim announce collaboration VEEV Veeva $165.49 / +2.58 (+1.58%) 05/25/23 KeyBanc Veeva price target lowered to $185 from $200 at KeyBanc 05/22/23 UBS Veeva price target lowered to $175 from $190 at UBS 03/17/23 Truist Veeva assumed at Hold from Buy at Truist 03/06/23 TD Cowen Veeva price target raised to $189 from $184 at TD Cowen VEEV Veeva $165.49 / +2.58 (+1.58%) 03/01/23 Veeva sees FY25 revenue 'at least' $2.8B 03/01/23 Veeva sees FY24 adjusted EPS about $4.33, consensus $4.46 03/01/23 Veeva sees Q1 adjusted EPS 79c-80c, consensus $1.00 03/01/23 Veeva reports Q4 adjusted EPS $1.15, consensus $1.04 VEEV Veeva $165.49 / +2.58 (+1.58%) 03/01/23 Fly Intel: After-Hours Movers 01/04/23 What You Missed On Wall Street On Wednesday 01/04/23 What You Missed On Wall Street This Morning 01/04/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/31/23 Veeva - VEEV 06/21/23 Veeva Systems Inc. VEEV Veeva $165.49 / +2.58 (+1.58%) 12/01/22 Veeva options imply 7.3% move in share price post-earnings
Hot Stocks	GreenLight to be acquired by consortium led by Fall Line in $45.5M transaction » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 GRNA GreenLight Bioscences / + GreenLight Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals GRNA GreenLight Bioscences / + 05/11/23 GreenLight Bioscences expects cash to fund operations into Q2 of 2023 02/01/23 GreenLight receives approval to initiate Phase I/II trial of COVID-19 vaccine 01/09/23 GreenLight Bioscences, Epivax signs exclusive collaboration agreement GRNA GreenLight Bioscences / + 04/03/23 Credit Suisse GreenLight Bioscences downgraded to Neutral from Outperform at Credit Suisse 12/08/22 Canaccord GreenLight Bioscences initiated with a Buy at Canaccord 10/14/22 Credit Suisse GreenLight Bioscences initiated with an Outperform at Credit Suisse GRNA GreenLight Bioscences / + 05/11/23 GreenLight Bioscences reports Q1 EPS (19c) vs (34c) last year GRNA GreenLight Bioscences / + 12/08/22 GreenLight Bio CEO says rebuffed take-private interest, Dealreporter reports

Downgrade	NeoGames downgraded to Neutral from Outperform at Macquarie » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 NGMS NeoGames $27.28 / +0.01 (+0.04%) Macquarie analyst Chad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly NGMS NeoGames $27.28 / +0.01 (+0.04%) 05/14/23 Fly Intel: Top five weekend stock stories 05/14/23 Neogames to be acquired by Aristocrat for $29.50 per share in cash 04/28/23 Neogames receives notice of deficiency from Nasdaq 04/10/23 Neogames, Caesars Entertainment extend agreement on NeoSphere platform NGMS NeoGames $27.28 / +0.01 (+0.04%) 05/18/23 Stifel NeoGames downgraded to Hold from Buy at Stifel 05/17/23 Jefferies NeoGames downgraded to Hold from Buy at Jefferies 05/16/23 BofA Sportradar price target raised to $11.50 from $10 at BofA 05/15/23 Truist Neogames downgraded to Hold from Buy at Truist NGMS NeoGames $27.28 / +0.01 (+0.04%) 05/10/23 Neogames reports Q1 adjusted EPS 20c, may not compare to consensus 1c 03/06/23 Neogames reports Q4 adjusted EPS 22c, consensus (13c) NGMS NeoGames $27.28 / +0.01 (+0.04%) 05/15/23 What You Missed On Wall Street On Monday 05/15/23 What You Missed On Wall Street This Morning 05/15/23 Fly Intel: Pre-market Movers 04/14/23 Bet On It: MGM gets step closer to $10B development plan in Japan
Hot Stocks	Trevena announces near-term milestones » 07:04 05/30/23 05/30 07:04 05/30/23 07:04 TRVN Trevena $1.14 / +0.05 (+4.59%) The Company also… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:04 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events TRVN Trevena $1.14 / +0.05 (+4.59%) 07:04 Today Trevena regains compliance with Nasdaq listing requirements 05/15/23 Trevena expects cash to fund requirements through 2023 05/08/23 Trevena announces approval of OLINVYK in China 03/30/23 Trevena announces OLINVYK data from real-world clinical outcomes study TRVN Trevena $1.14 / +0.05 (+4.59%) 03/31/23 H.C. Wainwright Trevena price target lowered to $9 from $11 at H.C. Wainwright TRVN Trevena $1.14 / +0.05 (+4.59%) 05/15/23 Trevena reports Q1 EPS (81c), consensus (98c) 03/30/23 Trevena reports Q4 EPS (73c) vs. ($2.12) last year TRVN Trevena $1.14 / +0.05 (+4.59%) 05/10/23 Biotech Alert: Searches spiking for these stocks today 06/15/23 Trevena, Inc.
Hot Stocks	Trevena regains compliance with Nasdaq listing requirements » 07:04 05/30/23 05/30 07:04 05/30/23 07:04 TRVN Trevena $1.14 / +0.05 (+4.59%) Trevena announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:04 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events TRVN Trevena $1.14 / +0.05 (+4.59%) 05/15/23 Trevena expects cash to fund requirements through 2023 05/08/23 Trevena announces approval of OLINVYK in China 03/30/23 Trevena announces OLINVYK data from real-world clinical outcomes study 03/30/23 Trevena expects cash to fund requirements into 4Q23 TRVN Trevena $1.14 / +0.05 (+4.59%) 03/31/23 H.C. Wainwright Trevena price target lowered to $9 from $11 at H.C. Wainwright TRVN Trevena $1.14 / +0.05 (+4.59%) 05/15/23 Trevena reports Q1 EPS (81c), consensus (98c) 03/30/23 Trevena reports Q4 EPS (73c) vs. ($2.12) last year TRVN Trevena $1.14 / +0.05 (+4.59%) 05/10/23 Biotech Alert: Searches spiking for these stocks today 06/15/23 Trevena, Inc.
Hot Stocks	Plus Therapeutics announces results from recurrent glioblastoma analysis » 07:03 05/30/23 05/30 07:03 05/30/23 07:03 PSTV Plus Therapeutics $4.28 / +0.03 (+0.71%) Plus Therapeutic… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:03 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PSTV Plus Therapeutics $4.28 / +0.03 (+0.71%) 05/16/23 Plus Therapeutics regains compliance with Nasdaq listing requirements 05/02/23 Plus Therapeutics expands collaboration with Piramal Pharma Solutions 04/28/23 Plus Therapeutics announce reverse stock split 04/19/23 Plus Therapeutics completes enrollment in Cohort 8 of ReSPECT-GBM Phase 1/2a PSTV Plus Therapeutics $4.28 / +0.03 (+0.71%) 05/03/23 Maxim Plus Therapeutics price target lowered to $12 from $30 at Maxim 10/06/22 JonesTrading Plus Therapeutics initiated with a Buy at JonesTrading 07/22/22 H.C. Wainwright Plus Therapeutics price target lowered to $3.50 from $7 at H.C. Wainwright PSTV Plus Therapeutics $4.28 / +0.03 (+0.71%) 04/20/23 Plus Therapeutics reports Q1 EPS (14c), consensus (13c)
Recommendations	Corvus Pharmaceuticals price target raised to $10 from $4 at Ladenburg » 07:03 05/30/23 05/30 07:03 05/30/23 07:03 CRVS Corvus Pharmaceuticals $2.60 / -0.195 (-6.99%) Ladenburg raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:03 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CRVS Corvus Pharmaceuticals $2.60 / -0.195 (-6.99%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 CRVS Corvus Pharmaceuticals $2.60 / -0.195 (-6.99%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald CRVS Corvus Pharmaceuticals $2.60 / -0.195 (-6.99%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 06/12/23 Biotech/Biopharma 06/15/23 Corvus Pharmaceuticals, Inc.
Earnings	MediWound reports Q1 EPS (44c), consensus (30c) » 07:02 05/30/23 05/30 07:02 05/30/23 07:02 MDWD MediWound $9.56 / +0.06 (+0.63%) Reports Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:02 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events MDWD MediWound $9.56 / +0.06 (+0.63%) 05/09/23 MediWound announces $10M award from BARDA 04/26/23 MediWound to present Phase 2 EscharEx data at SAWC Spring 2023 03/16/23 MediWound appoints Hani Luxenburg as CFO 03/06/23 MediWound appoints Barry Wolfenson as EVP, strategy and corporate development MDWD MediWound $9.56 / +0.06 (+0.63%) 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 12/30/22 Cowen MediWound price target raised to $25 from $6 at Cowen 12/29/22 Oppenheimer MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer 12/22/22 Maxim MediWound initiated with a Buy at Maxim MDWD MediWound $9.56 / +0.06 (+0.63%) 03/16/23 MediWound reports Q4 EPS ($1.18), consensus (59c) MDWD MediWound $9.56 / +0.06 (+0.63%) 12/22/22 Biotech Alert: Searches spiking for these stocks today 08:30 Today MediWound - MDWD
Hot Stocks	MagnaChip plans to separate display and power businesses into separate entities » 07:02 05/30/23 05/30 07:02 05/30/23 07:02 MX MagnaChip $10.66 / +0.39 (+3.80%) Magnachip Semiconductor… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:02 Get Free Trial ShowHide Related Items >><< Company News Earnings On The Fly Events MX MagnaChip $10.66 / +0.39 (+3.80%) 05/01/23 MagnaChip announces CFO Shin Young Park went on maternity leave 03/21/23 MagnaChip begins mass production of MOSFET1 02/17/23 MagnaChip falls -9.3% MX MagnaChip $10.66 / +0.39 (+3.80%) 05/03/23 MagnaChip reports Q1 EPS (24c), consensus (27c) 02/16/23 MagnaChip sees Q1 revenue $55M-$59M ,consensus $63.63M 02/16/23 MagnaChip reports Q4 non-GAAP EPS 36c, consensus (20c) MX MagnaChip $10.66 / +0.39 (+3.80%) 02/16/23 Fly Intel: After-Hours Movers 06/07/23 MagnaChip 06/08/23 MagnaChip 06/12/23 MagnaChip 06/13/23 MagnaChip
Upgrade	Ayala Pharmaceuticals upgraded to Buy from Neutral at Ladenburg » 07:02 05/30/23 05/30 07:02 05/30/23 07:02 ADXS Ayala Pharmaceuticals / + Ladenburg analyst Ahu… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:02 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ADXS Ayala Pharmaceuticals / + 03/03/23 Ayala Pharmaceuticals announces continuation of RINGSIDE Phase 2/3 study 01/19/23 Advaxis, Ayala Pharmaceuticals complete merger 01/12/23 Advaxis announces expansion of enrollment at second dose level in ADXS-504 trial ADXS Ayala Pharmaceuticals / + 10/31/22 Oppenheimer Ayala Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer 10/19/22 Roth Capital Ayala Pharmaceuticals downgraded to Sell from Buy at Roth Capital ADXS Ayala Pharmaceuticals / + 02/10/23 Ayala Pharmaceuticals reports FY22 EPS ($8.46) vs ($11.07) last year ADXS Ayala Pharmaceuticals / + 05/19/23 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	Bristol-Myers' repotrectinib application in lung cancer accepted by FDA » 07:01 05/30/23 05/30 07:01 05/30/23 07:01 BMY Bristol-Myers $63.82 / -0.735 (-1.14%) Bristol Myers announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:01 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination 05/25/23 Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl 05/25/23 Bristol-Myers says Breyanzi first and only CAR-T to deliver efficacy in CLL/SLL 05/25/23 Agios Pharmaceuticals appoints Owen to board of directors BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open 04/26/23 Notable companies reporting before tomorrow's open BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 06/02/23 2023 ASCO Annual Meeting 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY Bristol-Myers $63.82 / -0.735 (-1.14%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Initiation	Embecta assumed with an Underweight at Morgan Stanley » 07:01 05/30/23 05/30 07:01 05/30/23 07:01 EMBC Embecta $26.90 / -0.31 (-1.14%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:01 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly EMBC Embecta $26.90 / -0.31 (-1.14%) 05/12/23 Embecta, Tidepool partner to develop automated insulin delivery system 01/25/23 Embecta opens new global headquarters in Parsippany, New Jersey EMBC Embecta $26.90 / -0.31 (-1.14%) 01/06/23 Morgan Stanley Morgan Stanley cuts 'longer-term execution story' Embecta to Underweight 01/06/23 Morgan Stanley Embecta downgraded to Underweight from Equal Weight at Morgan Stanley 09/08/22 BTIG Embecta initiated with a Neutral at BTIG 08/01/22 Morgan Stanley Embecta initiated with an Equal Weight at Morgan Stanley EMBC Embecta $26.90 / -0.31 (-1.14%) 05/12/23 Embecta raises FY23 adjusted EPS view to $2.50-$2.60 from $2.20-$2.35 05/12/23 Embecta reports Q1 adjusted EPS 75c, consensus 49c 02/14/23 Embecta reports Q1 adjusted EPS 96c, consensus 51c 12/20/22 Embecta sees FY23 adjusted EPS $1.75-$2.00, consensus $3.11 EMBC Embecta $26.90 / -0.31 (-1.14%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/20/22 Fly Intel: Pre-market Movers

Initiation	Nevro assumed with an Equal Weight at Morgan Stanley » 07:00 05/30/23 05/30 07:00 05/30/23 07:00 NVRO Nevro $26.45 / -0.205 (-0.77%) Morgan Stanley assumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:00 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly NVRO Nevro $26.45 / -0.205 (-0.77%) 04/27/23 Nevro falls -9.9% 04/24/23 Nevro announces enrollment of first patient in PDN sensory study 04/20/23 Nevro falls -17.4% 04/20/23 Nevro falls -14.7% NVRO Nevro $26.45 / -0.205 (-0.77%) 05/18/23 Truist Nevro price target lowered to $32 from $40 at Truist 05/15/23 Oppenheimer Oppenheimer upgrades Nevro to Outperform, says risk-reward fairly balanced 05/15/23 Oppenheimer Nevro upgraded to Outperform from Perform at Oppenheimer 04/27/23 Piper Sandler Nevro price target lowered to $34 from $37 at Piper Sandler NVRO Nevro $26.45 / -0.205 (-0.77%) 04/26/23 Nevro backs FY23 revenue view $445M-$455M, consensus $448.91M 04/26/23 Nevro sees Q2 $110M-$112M, consensus $111.52M 04/26/23 Nevro reports Q1 EPS (98c), consensus ($1.04) 04/19/23 Nevro backs FY23 revenue view $445M-$455M, consensus $448.91M NVRO Nevro $26.45 / -0.205 (-0.77%) 04/20/23 What You Missed On Wall Street On Thursday 04/20/23 What You Missed On Wall Street This Morning 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning
Initiation	Inari Medical assumed with an Overweight at Morgan Stanley » 06:59 05/30/23 05/30 06:59 05/30/23 06:59 NARI Inari Medical $59.00 / -0.49 (-0.82%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 06:59 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NARI Inari Medical $59.00 / -0.49 (-0.82%) 05/22/23 Inari Medical announces planned enrollment of PEERLESS II trial 03/06/23 Inari Medical announces results from FLAME study 01/19/23 Inari Medical director sells $3.68M in common stock 01/12/23 Inari:1st patient enrolled in 'clinical outcomes' study of ClotTriever for DVT NARI Inari Medical $59.00 / -0.49 (-0.82%) 05/04/23 Canaccord Inari Medical price target raised to $84 from $80 at Canaccord 04/18/23 Truist Inari Medical price target raised to $70 from $68 at Truist 02/28/23 Canaccord Inari Medical price target raised to $80 from $77 at Canaccord 02/21/23 Canaccord Inari Medical price target raised to $77 from $76 at Canaccord NARI Inari Medical $59.00 / -0.49 (-0.82%) 05/03/23 Inari Medical raises FY23 revenue view to $478M-$488M from $470M-$480M 05/03/23 Inari Medical reports Q1 EPS (4c), consensus (23c) 02/27/23 Inari Medical sees FY23 revenue $470M-$480M, consensus $465.34M 02/27/23 Inari Medical reports Q4 EPS (11c), consensus (17c)
Initiation	iRhythm assumed with an Overweight at Morgan Stanley » 06:58 05/30/23 05/30 06:58 05/30/23 06:58 IRTC iRhythm $119.31 / -1.51 (-1.25%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 06:58 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly IRTC iRhythm $119.31 / -1.51 (-1.25%) 05/22/23 iRhythm announces presentation of four new studies as Hearth Rythum 2023 03/15/23 iRhythm COO Douglas Devine steps down 03/10/23 iRhythm provides update on investments with SVB Financial 03/06/23 iRhythm announces results of multiple new studies at ACC.23/WCC IRTC iRhythm $119.31 / -1.51 (-1.25%) 05/05/23 Canaccord iRhythm price target raised to $153 from $143 at Canaccord 05/05/23 Needham iRhythm price target raised to $151 from $133 at Needham 05/05/23 Citi iRhythm price target raised to $135 from $130 at Citi 04/17/23 Truist iRhythm price target raised to $154 from $137 at Truist IRTC iRhythm $119.31 / -1.51 (-1.25%) 05/04/23 iRhythm reports Q1 EPS ($1.29), consensus (90c) 03/15/23 iRhythm affirms FY23 revenue view of $475M-$485M, consensus $482.2M 02/23/23 iRhythm Sees FY23 revenue $475M-$485M, consensus $485.6M 02/23/23 iRhythm reports Q4 EPS (67c), consensus (62c) IRTC iRhythm $119.31 / -1.51 (-1.25%) 02/07/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Initiation	Axonics assumed with an Overweight at Morgan Stanley » 06:58 05/30/23 05/30 06:58 05/30/23 06:58 AXNX Axonics $48.52 / -1.03 (-2.08%) Morgan Stanley assumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 06:58 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events AXNX Axonics $48.52 / -1.03 (-2.08%) 04/24/23 Axonics acquired assets of Radian, terms not disclosed 01/31/23 Axonics receives FDA approval for rechargeable sacral neuromodulation system 12/13/22 Axonics announces Health Canada approval of R20 neurostimulator AXNX Axonics $48.52 / -1.03 (-2.08%) 05/23/23 CL King Axonics initiated with Buy on 'underpenetrated markets' at CL King 05/23/23 CL King Axonics initiated with a Buy at CL King 05/02/23 Needham Axonics price target raised to $73 from $71 at Needham 04/17/23 Truist Axonics price target lowered to $73 from $82 at Truist AXNX Axonics $48.52 / -1.03 (-2.08%) 05/01/23 Axonics raises FY23 revenue view to $348M from $324M, consensus $347.8M 05/01/23 Axonics reports Q1 EPS (19c), consensus (29c) 03/01/23 Axonics backs FY23 revenue view of $342M, consensus $336.4M 03/01/23 Axonics reports Q4 EPS 1c, consensus (24c) 03 Aug AXNX Axonics $48.52 / -1.03 (-2.08%) 05/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/01/23 Fly Intel: After-Hours Movers 03/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/11/23 What You Missed On Wall Street On Wednesday 06/26/23 Axonics Inc
Recommendations	Insperity price target lowered to $120 from $131 at Baird » 06:57 05/30/23 05/30 06:57 05/30/23 06:57 NSP Insperity $110.43 / +0.2 (+0.18%) Baird analyst Mark Marcon… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 06:57 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NSP Insperity $110.43 / +0.2 (+0.18%) 05/24/23 Insperity announces 10% dividend increase to 57c per share 04/24/23 Insperity falls -7.4% 02/16/23 Insperity VP Herinks ells 5,000 shares of company stock NSP Insperity $110.43 / +0.2 (+0.18%) 04/27/23 Roth MKM Insperity price target raised to $147 from $144 at Roth MKM 04/24/23 Truist Insperity cut to Hold at Truist amid softening white collar labor trends 04/24/23 Truist Insperity downgraded to Hold from Buy at Truist 04/24/23 Truist Insperity downgraded to Hold from Buy at Truist NSP Insperity $110.43 / +0.2 (+0.18%) 04/26/23 Insperity sees FY23 EPS $5.62 - $6.39, consensus $5.66 04/26/23 Insperity sees Q2 EPS $1.16- $1.32, consensus $1.17 04/26/23 Insperity reports Q1 EPS $2.67, consensus $2.48 02/09/23 Insperity sees FY23 EPS $5.24-$6.30, consensus $5.32 NSP Insperity $110.43 / +0.2 (+0.18%) 04/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/13/23 Business Services Bus Tour

Events

Earnings calls, analyst events, roadshows and more

GLNG
Today at 08:00

Golar LNG - GLNG Conference Calls
BNR
Today at 08:00

Burning Rock Biotech - BNR Conference Calls
TIGR
Today at 08:00

UP Fintech - TIGR Conference Calls
GOTU
Today at 08:00

Gaotu Techedu - GOTU Conference Calls
TCRR
Today at 08:00

TCR2 Therapeutics Inc. Firm Sponsored Meetings
YTRA
Today at 08:30

Yatra - YTRA Conference Calls
MDWD
Today at 08:30

MediWound - MDWD Conference Calls
Today at 09:00

Case-Shiller Home Price Index: 20-City Unadjusted Y/Y: March 2023 Government Event
Today at 09:00

FHFA House Price Index M/M: March 2023 Government Event
Today at 09:00

FHFA House Price Index Y/Y: March 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	AZTR X AZTR Azitra IPO Managers: ThinkEquity $4.50-5.50 2.4M Shares SXTP X SXTP 60 Degrees Pharmaceuticals IPO Managers: WallachBeth $4.30-6.30 1.415M Shares
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

NaaS, Smart Order establish 'Smart Charging' joint venture

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access